A treatment consisting of benzamide derivatives has been developed to improve patient conditions and survival rates against chronic lymphocytic leukemia of B cells.

The Need

Chronic lymphocytic leukemia (CLL) of B-lymphocyte cells is the most common type of adult leukemia, which is an incurable disease developed within bone marrow. This disease prevents white blood cells from functioning normally and can lead to metastasis. B-CLL cells are inactive and accummulate over periods of time which interferes with the patient’s immune system, leading to fatal cytopenias and frequent infections caused by lowered normal blood cell levels. Current therapeutic options for B-CLL leukemia are limited once patients acquire resistance to one or more drugs, which can lead to remission of the disease. New drugs which induce apoptosis of B-CLL cells would increase the quality of life for patients suffering from B-CLL type leukemia and decrease the risk of metastasis.

The Market

  • In 2014, 15,720 new cases of chronic lymphocytic leukemia (CLL) will be diagnosed in the US. (CDC)
  • 70% of people diagnosed with CLL will require treatment to fight leukaemic cells. (Leukaemia Foundation)
  • The CLL therapeutics market worldwide was estimated at $554 million in 2012 and is expected to reach $814 million by 2017. (BCC Research)
  • CLL accounts for approximately 30% to 40% of all leukemias. (ISPOR, 2013)

The Technology

The Ohio State University researchers, led by Dr. David Lucas, developed a chemotherapeutic treatment which targets antigens present on B-CLL cells and utilizes synthetic benzamide derivatives capable of blocking growth in a variety of different kinds of tumor cells. This treatment will prevent malignant B-CLL cells from uncontrolled cell differentiation and help afflicted patients maintain normal levels of healthy blood cells.

  • New drug compound will improve the quality of life for patients afflicted with CLL
  • Clinical tests performed on cells taken from B-CLL patients prove that MS-275, a benzamide derivative, has selective activity against B-CLL cells in comparison to normal cells
  • Method with one or more benzamide derivative agents will induce apoptosis in B-CLL cells

Interested in this Technology?

Submit your interest below